NCT02212782

the Pharmacokinetic Profiles of Linagliptin With DW1029M

A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Linagliptin After Oral Administration in Healthy Male Volunteer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Dong Wha Pharmaceutical Co. Ltd. · Industry
• Sex: Male
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Linagliptin after oral administration in healthy male volunteer.

Detailed description

A Randomized, open-label, multiple-dose, crossover phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Linagliptin after oral administration in healthy male volunteer.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Linagliptin 5mg	Linagliptin 5mg once daily for 7 days
DRUG	DW1029M 1200mg and Linagliptin 5mg	Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days

Timeline

• Start date: 2014-09-01
• Primary completion: 2014-11-01
• Completion: 2015-01-01
• First posted: 2014-08-08
• Last updated: 2015-06-29

Locations

1 site across 1 country: South Korea